<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20251007067533N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-10-19</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Intraperitoneal Dexamethasone Combined with Bupivacaine plus a Pulmonary Maneuver on Common Complications Following Laparoscopic Cholecystectomy</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the Effect of Intraperitoneal Dexamethasone Combined with Bupivacaine along with Lung Recruitment Maneuver Positioning on Pain, Nausea and Vomiting after Laparoscopic Cholecystectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/86691</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patient allocation into the four groups will be performed using block randomization with a block size of eight. The randomization list will be generated by the online tool at https://www.sealedenvelope.com. Within this software, the random allocation sequence is automatically produced in the ‘Create a randomization list’ section after specifying the intervention types, block size, and total sample size. To ensure allocation concealment, the randomization list will be managed by an independent third party who is not involved in the core research activities. This procedure will prevent the disclosure of the allocation sequence to the research team members before the patient is definitively assigned to an intervention group, Blinding description: In this study, both the patients and the outcome assessors will be blinded to the group allocation. Patients will be unaware of whether they are in an intervention group or the control group, and the outcome assessors will be unaware of the specific group assignment for each patient. Therefore, this study is a double-blind, randomized controlled trial.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Postoperative Abdominal Pain After Laparoscopic Cholecystectomy. Condition 2: Postoperative Nausea and Vomiting after Laparoscopic Cholecystectomy. Condition 3: Postoperative Shoulder Pain After Laparoscopic Cholecystectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group one: At the end of the surgery, before the removal of the cannulas and the closure of the incision sites in the abdomen, by changing the reverse Trendelenburg position to the supine position, the Pulmonary Recruitment Maneuver will be administered with 5 high-volume manual breaths until the airway pressure reaches 40 cmH2O. This pressure is maintained for 5 seconds in the supine position. This level of airway pressure is set on the Drager Fabius Plus anesthesia machine and then measured until the desired tidal volume is reached. The cannula valves will be open during the maneuver for CO2 gas to be evacuated. Intervention 2: Intervention group two: At the end of the surgery, before the removal of the cannulas and the closure of the incision sites in the abdomen, 40 cc of 0.25% Bupivacaine combined with 16 mg of Dexamethasone will be injected intraperitoneally. Then, for drug distribution, the patient’s position will be changed from reverse Trendelenburg to the Trendelenburg position. For drug distribution through position change, the patients will remain in the Trendelenburg position for 10 minutes. Intervention 3: Intervention group three: At the end of the surgery, before the removal of the cannulas and the closure of the incision sites in the abdomen,  first, 40 cc of 0.25% Bupivacaine combined with 16 mg of Dexamethasone will be injected intraperitoneally. For drug distribution, the patient’s position will be changed from reverse Trendelenburg to the Trendelenburg position, and the patient will be kept in the Trendelenburg position for 10 minutes; then, by changing the position from Trendelenburg to the supine position, the Pulmonary Recruitment Maneuver for CO2 gas evacuation will be performed with 5 high-volume manual breaths until the airway pressure reaches 40 cmH2O. This pressure is maintained for 5 seconds in the supine position. This level of airway pressure is set on the Drager Fabius Plus anesthesia machine and then measured until the desired tidal volume is reached. The cannula valves will be open during the maneuver for CO2 gas to be evacuated. Intervention 4: Control group: Laparoscopic cholecystectomy will be performed according to the surgeon’s standard and routine method, without any additional intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The privacy and confidentiality of all participants’ identifying information will be guaranteed throughout every stage of the research, and only anonymized codes will be utilized during data analysis. The dissemination of this study’s findings is contingent upon obtaining permission from the Research Ethics Committee of Mazandaran University of Medical Sciences and adhering strictly to all established ethical principles and guidelines.

When:
Beginning of the access period from 2026

To whom:
Researchers affiliated with academic and accredited research institutions

Conditions:
The de-identified dataset from this study will be made available to qualified researchers upon formal email request to the corresponding author. The research team is committed to maintaining the absolute confidentiality of the original patient data and will only report findings in an aggregated form, in accordance with ethical publication guidelines.

Where to obtain:
Interested researchers can request access to the study data by corresponding with the primary author via email.
Email: Diako8358@gmail.com

How to obtain:
Upon receiving a formal request via email, the corresponding author will review the conditions for data access. Following approval, the requested dataset will be made available to the applicant within a maximum period of two weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Miad Haddadian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 273, 3rd Golestan Aly., Modarres Ave., Hasankif Town</address>
        <city>Kelardasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4666471717</zip>
        <telephone>+98 11 5262 4342</telephone>
        <email>Diako8358@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Miad Haddadian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 273, 3rd Golestan Aly., Modarres Ave., Hasankif Town</address>
        <city>Kelardasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4666471717</zip>
        <telephone>+98 11 5262 4342</telephone>
        <email>Diako8358@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients undergoing elective laparoscopic cholecystectomy who have provided written informed consent
Aged 18 to 60 years
American Society of Anesthesiologists (ASA) physical status classification of I or II
Anticipated surgery duration of less than 2 hours
No known history of hypersensitivity to dexamethasone, bupivacaine, or anesthetic agents
Body Mass Index (BMI) &lt; 40 kg/m²</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients unwilling to participate or who decline to provide informed consent
Presence of any contraindication to the pulmonary recruitment maneuver
History of previous abdominal or shoulder surgery
History of opioid use, alcohol consumption, and long-term use of steroidal and non-steroidal anti-inflammatory drugs
History of chronic pain unrelated to gallbladder disease
Pregnancy or lactation
Presence of significant cardiovascular, pulmonary, renal, hepatic, neurological, or psychiatric diseases; diabetes mellitus; or inflammatory conditions of the shoulder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group one: At the end of the surgery, before the removal of the cannulas and the closure of the incision sites in the abdomen, by changing the reverse Trendelenburg position to the supine position, the Pulmonary Recruitment Maneuver will be administered with 5 high-volume manual breaths until the airway pressure reaches 40 cmH2O. This pressure is maintained for 5 seconds in the supine position. This level of airway pressure is set on the Drager Fabius Plus anesthesia machine and then measured until the desired tidal volume is reached. The cannula valves will be open during the maneuver for CO2 gas to be evacuated.</i_keyword>
      <i_keyword>Intervention group two: At the end of the surgery, before the removal of the cannulas and the closure of the incision sites in the abdomen, 40 cc of 0.25% Bupivacaine combined with 16 mg of Dexamethasone will be injected intraperitoneally. Then, for drug distribution, the patient’s position will be changed from reverse Trendelenburg to the Trendelenburg position. For drug distribution through position change, the patients will remain in the Trendelenburg position for 10 minutes.</i_keyword>
      <i_keyword>Intervention group three: At the end of the surgery, before the removal of the cannulas and the closure of the incision sites in the abdomen,  first, 40 cc of 0.25% Bupivacaine combined with 16 mg of Dexamethasone will be injected intraperitoneally. For drug distribution, the patient’s position will be changed from reverse Trendelenburg to the Trendelenburg position, and the patient will be kept in the Trendelenburg position for 10 minutes; then, by changing the position from Trendelenburg to the supine position, the Pulmonary Recruitment Maneuver for CO2 gas evacuation will be performed with 5 high-volume manual breaths until the airway pressure reaches 40 cmH2O. This pressure is maintained for 5 seconds in the supine position. This level of airway pressure is set on the Drager Fabius Plus anesthesia machine and then measured until the desired tidal volume is reached. The cannula valves will be open during the maneuver for CO2 gas to be evacuated.</i_keyword>
      <i_keyword>Control group: Laparoscopic cholecystectomy will be performed according to the surgeon’s standard and routine method, without any additional intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Abdominal Pain. Timepoint: At 2, 6, 12, 18, 24, and 48 hours postoperatively. Method of measurement: Visual Analog Scale.</prim_outcome>
      <prim_outcome>Shoulder Pain. Timepoint: At 2, 6, 12, 18, 24, and 48 hours postoperatively. Method of measurement: Visual Analog Scale.</prim_outcome>
      <prim_outcome>Postoperative Nausea and Vomiting. Timepoint: At 2, 6, 12, 18, 24, and 48 hours postoperatively. Method of measurement: Emesis Score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-09-22</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Sari School of Allied Medical Sciences, Mazandaran University of Medical Sciences, Payambar-e-Azam University Complex, 17th Kilometer of Khazarabad Road, Khazar Square Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
